<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03195270</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-24972</org_study_id>
    <nct_id>NCT03195270</nct_id>
  </id_info>
  <brief_title>Use of PET/MR Imaging in Chronic Pain</brief_title>
  <official_title>Use of [18F]FDG PET/MRI in the Diagnosis of Pain Generators and/or Sites of Inflammation and to Monitor Treatment Effects in Patients With Chronic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are studying the ability of PET/MR imaging (using the PET tracer [18F]FDG)&#xD;
      to objectively identify and characterize pain generators in patients suffering from chronic&#xD;
      pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The diagnosis and management of chronic and neuropathic pain syndromes remains a major&#xD;
      clinical challenge, and this failure is partly attributed to our inability to identify the&#xD;
      hypersensitive and inflammatory changes in the pain-sensing part of our nervous system that&#xD;
      is thought to contribute to these syndromes. The lack of a specific, objective diagnostic&#xD;
      test for chronic and neuropathic pain syndromes can result in a delay of diagnosis and&#xD;
      suboptimal management decisions. This delay in diagnosis is quite unfortunate since the early&#xD;
      diagnosis and treatment of a disease is attributed to the highest probability of remission in&#xD;
      certain chronic pain syndromes. Additionally, identifying the correct source of pain is of&#xD;
      paramount importance since the clinical course and therapeutic interventions are different&#xD;
      depending on cause.&#xD;
&#xD;
      Evidence in the literature points strongly toward an active inflammatory component in chronic&#xD;
      pain. For example, soft tissue and bony inflammation is known to be an important&#xD;
      pathophysiological mechanism for the symptoms of certain neuropathic pain syndromes.&#xD;
      Similarly, individuals suffering from chronic sciatica or radiculopathy may suffer from a&#xD;
      combination of inflammation and compression of lumbar or cervical spinal nerves. It is also&#xD;
      established that inflammatory lesions have increased metabolism and energy requirements and,&#xD;
      therefore, are more glucose-avid than normal tissues, showing increased uptake of&#xD;
      radiolabeled glucose analogs, such as [18F]fluorodeoxyglucose ([18F]FDG). Correspondingly,&#xD;
      [18F]FDG positron emission tomography-magnetic resonance imaging (PET/MRI) represent leading&#xD;
      FDA-approved clinical imaging modalities to longitudinally study metabolic changes in the&#xD;
      nervous system and non-neural tissues (e.g., muscle, blood vessels, joints, bone, scar&#xD;
      tissue, etc.) in patients with chronic pain conditions. One of the goals of the study is to&#xD;
      determine whether [18F]FDG PET/MRI can identify sources of inflammation with greater&#xD;
      sensitivity, accuracy and objectivity than current diagnostic methods.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 24, 2014</start_date>
  <completion_date type="Anticipated">January 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Participants will be recruited based on established criteria for chronic pain. For the PET/MRI scan, the participants will be injected with 10 mCiÂ±1 mCi of [18F]FTC-146 via the antecubital vein in a bolus injection. PET and MRI scans will be acquired simultaneously using a hybrid PET/MRI scanner. Following the scan, participants will be contacted to check for adverse drug events, and any events will be recorded in the case report. The biodistribution of radiotracer will be analyzed using regions of interest (ROI) marked on anatomical structures on magnetic resonance images and quantifying the signal in PET images within the same ROIs. Pharmacokinetic information will be derived using mathematical modeling. Data from chronic pain patients will be compared to historical data from asymptomatic controls.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>[18F]FDG PET/MRI as a spatial biomarker for chronic pain</measure>
    <time_frame>5 years</time_frame>
    <description>Identification of structures with increased [18F]FDG uptake (SUVmax) corresponding to pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>[18F]FDG Biodistribution in Healthy Subjects</measure>
    <time_frame>5 years</time_frame>
    <description>We will use PET/MRI to establish the normal range of [18F]FDG uptake. (SUVmax) in various anatomic structures, such as the spinal cord, peripheral nerves, dorsal root ganglia, muscle, bones, joints, blood vessels, of asymptomatic subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36 point Study Short-Form Health Survey</measure>
    <time_frame>5 years</time_frame>
    <description>Patient-reported state of health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oswestry Disability Index</measure>
    <time_frame>5 years</time_frame>
    <description>Measure of disability, quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale</measure>
    <time_frame>5 years</time_frame>
    <description>A visual, semi-quantitative method for patient-derived self-assessment of pain intensity.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[18F]FDG PET/MRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]FDG</intervention_name>
    <description>10 mCi of [18F]FDG via the antecubital vein in a bolus injection</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>[18F]Fluorodeoxyglucose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PET/MRI</intervention_name>
    <description>PET/MRI hybrid scanner used as diagnostic device</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>Positron emission tomography/magnetic resonance imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older.&#xD;
&#xD;
          -  Chronic pain lasting greater than 2 months. For example: Low back pain, sciatica,&#xD;
             complex regional pain syndrome, peripheral nerve injury, fibromyalgia, neuropathy,&#xD;
             osteoarthritis, cancer pain, persistent post-operative pain, and migraine.&#xD;
&#xD;
          -  Provides informed consent&#xD;
&#xD;
          -  On a typical day, pain level of at least 4/10 on a 0-10 Comparative Pain Scale&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  MRI-incompatible.&#xD;
&#xD;
          -  Diabetes.&#xD;
&#xD;
          -  Pregnant or nursing.&#xD;
&#xD;
          -  Non-English speaker.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandip Biswal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor of Radiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandip Biswal, MD</last_name>
    <phone>650-725-8018</phone>
    <email>biswal@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sunyoung Park, BA</last_name>
    <email>sydoit@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ian Carroll, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine Curtin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vivanne Tawfik, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Smuck, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ivan Cheng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stuart Goodman, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erik Mittra, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>DaeHyun Yoon, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Garry Gold, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Behera D, Jacobs KE, Behera S, Rosenberg J, Biswal S. (18)F-FDG PET/MRI can be used to identify injured peripheral nerves in a model of neuropathic pain. J Nucl Med. 2011 Aug;52(8):1308-12. doi: 10.2967/jnumed.110.084731. Epub 2011 Jul 15.</citation>
    <PMID>21764788</PMID>
  </reference>
  <reference>
    <citation>Do BH, Mari C, Tseng JR, Quon A, Rosenberg J, Biswal S. Pattern of 18F-FDG uptake in the spinal cord in patients with non-central nervous system malignancy. Spine (Phila Pa 1976). 2011 Oct 1;36(21):E1395-401. doi: 10.1097/BRS.0b013e31820a7df8.</citation>
    <PMID>21311407</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 19, 2017</study_first_submitted>
  <study_first_submitted_qc>June 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2017</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Sandip Biswal</investigator_full_name>
    <investigator_title>Associate Professor of Radiology</investigator_title>
  </responsible_party>
  <keyword>Positron emission tomography</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>PET/MRI</keyword>
  <keyword>Fluorodeoxyglucose</keyword>
  <keyword>FDG</keyword>
  <keyword>Pain</keyword>
  <keyword>Chronic Pain</keyword>
  <keyword>Neuropathic Pain</keyword>
  <keyword>Inflammatory Pain</keyword>
  <keyword>Nociceptive Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is currently no plan to share the individual participant data with other researchers outside our group of researchers or referring physicians.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

